Alliancebernstein L.P. Increases Stock Position in Stryker Corporation $SYK

Alliancebernstein L.P. raised its stake in shares of Stryker Corporation (NYSE:SYK) by 13.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,338,050 shares of the medical technology company’s stock after purchasing an additional 741,542 shares during the period. Stryker accounts for approximately 0.7% of Alliancebernstein L.P.’s holdings, making the stock its 18th biggest position. Alliancebernstein L.P. owned 1.66% of Stryker worth $2,342,987,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in SYK. Clayton Financial Group LLC purchased a new stake in shares of Stryker in the third quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the 3rd quarter valued at approximately $27,000. Elevation Point Wealth Partners LLC bought a new stake in Stryker in the 2nd quarter worth approximately $28,000. Kilter Group LLC bought a new stake in Stryker in the 2nd quarter worth approximately $29,000. Finally, Howard Hughes Medical Institute purchased a new stake in shares of Stryker during the 2nd quarter worth approximately $29,000. 77.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on SYK. Needham & Company LLC raised their target price on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a report on Friday, January 30th. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research note on Friday, January 30th. Piper Sandler reiterated an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Sanford C. Bernstein lifted their price objective on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $428.61.

Stryker Trading Down 0.1%

SYK opened at $336.95 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock’s 50 day moving average price is $365.20 and its 200-day moving average price is $367.52. Stryker Corporation has a one year low of $328.23 and a one year high of $404.87. The stock has a market cap of $128.95 billion, a price-to-earnings ratio of 40.11, a P/E/G ratio of 1.97 and a beta of 0.85.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.01 EPS. On average, equities analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.90% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Citi and some analysts view the pullback as a potential buying opportunity given Stryker’s fundamentals and upcoming catalysts — Citi put together a “90‑day catalyst watch” that sees upside despite the outage. Citi Sees Upside
• Positive Sentiment: Technicals may offer support: commentators note shares became oversold after the sell‑off and found support at a prior level, suggesting a possible technical bounce for traders. Stock Of The Day: Where Is The Bottom For Stryker?
• Neutral Sentiment: Stryker has publicly confirmed a cybersecurity incident and is investigating; the company is communicating updates as the situation evolves. Company Announcement
• Neutral Sentiment: Reporting shows the attack is causing real operational disruption to order processing, manufacturing and shipments — facts investors must watch to judge duration and revenue impact. Reuters: Disruption Report
• Negative Sentiment: Hackers claiming Iran linkage (group “Handala”) say the attack included destructive “wiper” activity and exfiltration of large volumes of data — allegations that raise the risk of extended downtime and regulatory/PR fallout. IBTimes: Hacker Claim
• Negative Sentiment: Operational paralysis from the incident has already pressured the stock, with multiple outlets reporting multi‑percent intraday declines as orders and shipments stall. Yahoo: Shares Fall
• Negative Sentiment: Social‑media driven selling amplified volatility — a viral Reddit thread and related headlines accelerated the recent drop, adding short‑term downside risk beyond fundamentals. 24/7 Wall St.: Reddit Impact

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.